Novartis Investigative Site

Brighton, East Sussex BN2 5BE

2 studies enrolling now · 8 studies all time

What they study most

Atrial Fibrillation, Breast Cancer, HER2+ Breast Cancer, Heart Failure With Reduced Ejection Fraction, IgA Nephropathy, Immunoglobulin A Nephropathy, Lymphangioleiomyomatosis (LAM), Metastatic Breast Cancer, Relapsing Forms of Multiple Sclerosis, Secondary Progressive Multiple Sclerosis (SPMS), Tuberous Sclerosis Complex (TSC)

Studies at this site

• A Study to Investigate the Efficacy, Safety, Tolerability and Pharmacokinetics of PKN605 in Participants With Atrial Fibrillation — Recruiting now
• A Study to Evaluate the Efficacy and Safety of Remibrutinib in Secondary Progressive Multiple Sclerosis — Recruiting now
• A Study of Zigakibart in Adults With IgA Nephropathy — Running, not enrolling
• Long-term Safety and Tolerability of 0.5 mg Fingolimod in Patients With Relapsing Forms of Multiple Sclerosis — Completed
• Efficacy and Safety of RAD001 in Patients Aged 18 and Over With Angiomyolipoma Associated With Either Tuberous Sclerosis Complex (TSC) or Sporadic Lymphangioleiomyomatosis (LAM) — Completed
• A Randomized, Phase 2, Neoadjuvant Study of Weekly Paclitaxel With or Without LCL161 in Patients With Triple Negative Breast Cancer — Completed
• Phase 1b/2 Study of BKM120 Plus Trastuzumab in Patients With HER2-positive Breast Cancer — Stopped early
• This Study Will Evaluate the Efficacy and Safety of LCZ696 Compared to Enalapril on Morbidity and Mortality of Patients With Chronic Heart Failure — Stopped early